Clinical Trials Sponsored by T3D Therapeutics, Inc.

Total 2985 results

Solace Therapeutics, Inc.

Completed

Vesair Continued Access Trial (VESICAL)

Stress Urinary Incontinence

United States
Repros Therapeutics Inc.

Terminated

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Seres Therapeutics, Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Healthy

United States
Lisata Therapeutics, Inc.

Withdrawn

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Brain and Central Nervous System Tumors

United States
Aclaris Therapeutics, Inc.

Completed

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Biosplice Therapeutics, Inc.

Terminated

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

Degenerative Disc Disease

United States
Esperion Therapeutics, Inc.

Completed

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Hyperlipidemia

United States
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, France, Denmark, Germany
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

COPD

Belgium
ACEA Therapeutics, Inc.

Completed

Study of AC0058TA in Healthy Male and Female Subjects

Healthy Volunteers

United States
Kartos Therapeutics, Inc.

Completed

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Acute Myeloid Leukemia | Cancer | Oncology | Advanced Malignancy | Oncology Patients

United States
Esperion Therapeutics, Inc.

Completed

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Hyperlipidemia

United Kingdom
INSYS Therapeutics Inc

Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

Healthy Volunteer

United States
INSYS Therapeutics Inc

Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

Healthy Volunteer

United States
Melinta Therapeutics, Inc.

Withdrawn

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (TANGOIII)

Hospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
Click Therapeutics, Inc.

Completed

Clinical Trial of Smoking Cessation Mobile Phone Program

Substance Use Disorder | Drug Addiction | Tobacco Dependence | Drug Dependence | Nicotine Addiction

United States
Travere Therapeutics, Inc.

Unknown

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

Cerebrotendinous Xanthomatosis (CTX)

United States
Tobira Therapeutics, Inc.

Completed

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

United States, Canada
Leap Therapeutics, Inc.

Completed

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Cholangiocarcinoma | Bile Duct Cancer | Carcinoma of Intrahepatic and Extra-hepatic Biliary System | Carcinoma of Gallbladder

United States
Biosplice Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Hepatic Cancer

United States
Relmada Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)

Neuropathic Pain
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Melinta Therapeutics, Inc.

Terminated

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

Gonorrhea

United States
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
Gila Therapeutics, Inc.

Completed

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

Feeding and Eating Disorders

United States
Axsome Therapeutics, Inc.

Unknown

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 (CREATE-1)

Reflex Sympathetic Dystrophy | Complex Regional Pain Syndrome

United States, United Kingdom, Australia, Canada
Obalon Therapeutics, Inc.

Completed

Obalon Balloon System Pivotal IDE (SMART) Trial (SMART)

Obesity

United States
InteKrin Therapeutics, Inc.

Completed

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

Multiple Sclerosis, Relapsing Remitting
CymaBay Therapeutics, Inc.

Completed

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Gout

United States, Canada, Georgia
CymaBay Therapeutics, Inc.

Terminated

Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis (PBC)

Germany, United States, Canada, United Kingdom, Poland
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Dravet Syndrome
Realm Therapeutics, Inc.

Unknown

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Avalo Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Major Depressive Disorder

United States
Chrono Therapeutics, Inc.

Completed

Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects

Smoking Cessation

United States
Tobira Therapeutics, Inc.

Completed

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Healthy

United States
Melinta Therapeutics, Inc.

Completed

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue Infections

United States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
Aciex Therapeutics, Inc.

Completed

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Allergic Conjunctivitis

United States
Millendo Therapeutics, Inc.

Completed

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Adrenocortical Carcinoma | Adrenal Cancer | ACC

United States, Germany
Anika Therapeutics, Inc.

Completed

Safety Study of Cosmetic Tissue Augmentation in People of Color

Wrinkles

United States
Aciex Therapeutics, Inc.

Completed

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Healthy

United States
Aciex Therapeutics, Inc.

Completed

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Atopic Disease (Including Allergic Conjunctivitis)

United States
INSYS Therapeutics Inc

Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Post-operative Pain

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Healthy Volunteers

Canada
INSYS Therapeutics Inc

Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Acute Pain

United States
Onconova Therapeutics, Inc.

Completed

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative Disease

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET)

Myelodysplastic Syndrome | MDS | Trisomy 8

United States
Onconova Therapeutics, Inc.

Completed

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States

3

Subscribe